Acrivon director receives 20,275 stock options

Acrivon Therapeutics director Ivana Magovcevic-Liebisch received a new stock option grant.

Rhea-AI Filing Summary

Acrivon Therapeutics director Ivana Magovcevic-Liebisch received a new stock option grant. She was granted options to acquire 20,275 shares of Acrivon Therapeutics common stock at an exercise price of $1.52 per share.

The options are a compensation-related award, not an open-market purchase. They vest on the date immediately preceding the company’s next annual meeting of stockholders, as long as she remains in continuous service through that vesting date. Following this grant, she holds stock options for 20,275 underlying shares directly.

Insider Trade Summary

Grant/Award: 20,275 shares

Grant/Award 1 txn

Insider Magovcevic-Liebisch Ivana

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,275	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,275 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

Key Figures

Option grant size: 20,275 shares Exercise price: $1.52 per share Total options after grant: 20,275 derivative securities +1 more

4 metrics

Option grant size 20,275 shares Stock Option (Right to Buy) underlying common stock

Exercise price $1.52 per share Conversion or exercise price of stock option

Total options after grant 20,275 derivative securities Total shares following transaction

Option expiration June 16, 2036 Expiration date of the stock option

Key Terms

Stock Option (Right to Buy), exercise price, derivative security, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.5200"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative security financial

"transaction_type: derivative"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vesting financial

"shares subject to the option shall vest on the date immediately preceding"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"date of the Issuer's next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Acrivon Therapeutics (ACRV) disclose in this Form 4 filing?

Acrivon Therapeutics reported a stock option grant to director Ivana Magovcevic-Liebisch. She received options covering 20,275 shares of common stock as a compensation-related award, documented as a derivative security transaction with no open-market buying or selling involved.

How many Acrivon Therapeutics (ACRV) shares are covered by the new option grant?

The new stock option grant covers 20,275 shares of Acrivon Therapeutics common stock. These options give the director the right to buy that number of shares in the future, subject to vesting and payment of the stated exercise price per share when exercised.

What is the exercise price of the Acrivon Therapeutics (ACRV) stock options granted?

The stock options were granted with an exercise price of $1.52 per share. This is the fixed price at which the director can buy Acrivon Therapeutics common stock once the options vest and she chooses to exercise them, according to the Form 4 disclosure.

When do the new Acrivon Therapeutics (ACRV) stock options vest?

The options vest on the date immediately preceding Acrivon Therapeutics’ next annual meeting of stockholders. Vesting is conditioned on Ivana Magovcevic-Liebisch continuing to provide service to the company through that vesting date, as described in the Form 4 footnote.

Is this Acrivon Therapeutics (ACRV) Form 4 a market purchase or sale of shares?

This Form 4 reflects a stock option grant, not an open-market purchase or sale. The transaction is coded as a grant or award acquisition, meaning the director received derivative securities as compensation rather than trading existing Acrivon Therapeutics shares in the market.

How many Acrivon Therapeutics (ACRV) options does the director hold after this grant?

After this grant, Ivana Magovcevic-Liebisch holds stock options covering 20,275 underlying shares. The Form 4 reports total derivative securities beneficially owned following the transaction as 20,275, all held directly, reflecting only this newly granted option position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Magovcevic-Liebisch Ivana

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.52	06/17/2026		A		20,275		(1)	06/16/2036	Common Stock	20,275	$0	20,275	D

Explanation of Responses:

1. The shares subject to the option shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through the applicable vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)